Advances in mobilization for the optimization of autologous stem cell transplantation

Leukemia and Lymphoma

Volumn 50, Issue 9, 2009, Pages 1412-1421

  Vose, Julie M ^a   Ho, Anthony D ^b   Coiffier, Bertrand ^c   Corradini, Paolo ^d   Khouri, Issa ^e   Sureda, Anna ^f   Van Besien, Koen ^g   Dipersio, John ^h  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c CENTRE HOSPITALIER LYON SUD   (France)

^d UNIVERSITY OF MILAN   (Italy)

^e UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^f Hospital Sant Pau   (Spain)

^g UNIVERSITY OF CHICAGO   (United States)

^h WASHINGTON UNIVERSITY   (United States)

Author keywords

Autologous stem cell transplantation; peripheral blood stem cell transplantation; peripheral blood stem cells

Indexed keywords

CD11B ANTIGEN; CD44V ANTIGEN; CHEMOKINE RECEPTOR CXCR4; CYCLOPHOSPHAMIDE; ERYTHROPOIETIN; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PLERIXAFOR; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; STEM CELL FACTOR; VERY LATE ACTIVATION ANTIGEN 4; ANTINEOPLASTIC AGENT; HETEROCYCLIC COMPOUND; IMMUNOLOGIC FACTOR;

AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER CHEMOTHERAPY; CD34 SELECTION; DISEASE FREE SURVIVAL; DRUG APPROVAL; GOLD STANDARD; HALF LIFE TIME; HEMATOLOGIC MALIGNANCY; HEMATOPOIETIC STEM CELL; HUMAN; MICROENVIRONMENT; MULTIPLE MYELOMA; OVERALL SURVIVAL; PERIPHERAL BLOOD STEM CELL; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; STEM CELL MOBILIZATION; AUTOTRANSPLANTATION; BIOLOGICAL MODEL; CALIBRATION; DEFENSE MECHANISM; METHODOLOGY; STANDARD; STEM CELL TRANSPLANTATION;

ANTINEOPLASTIC AGENTS; CALIBRATION; GRANULOCYTE COLONY-STIMULATING FACTOR; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HEMATOPOIETIC STEM CELL MOBILIZATION; HETEROCYCLIC COMPOUNDS; HUMANS; IMMUNOLOGIC FACTORS; MODELS, BIOLOGICAL; RATIONALIZATION; STEM CELL TRANSPLANTATION; TRANSPLANTATION, AUTOLOGOUS;

EID: 77952921898     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.1080/10428190903096701     Document Type: Review

References (120)

1. Arslan O, Moog R. Mobilization of peripheral blood stem cells. Transfus Apher Sci 2007;37:179-185. (Pubitemid 350181579)
2. Moog R. Management strategies for poor peripheral blood stem cell mobilization. Transfus Apher Sci 2008;38:229-236.
3. Kessinger A, Armitage JO, Landmark JD, et al. Reconstitution of human hematopoietic function with autologous cryopreserved circulating stem cells. Exp Hematol 1986;14:192-196. (Pubitemid 16109540)
4. Bensinger WI, Weaver CH, Appelbaum FR, et al. Transplantation of allogeneic peripheral blood stem cells mobilized by recombinant human granulocyte colony-stimulating factor. Blood 1995;85:1655-1658.
5. Korbling M, Przepiorka D, Huh YO, et al. Allogeneic blood stem cell transplantation for refractory leukemia and lymphoma: potential advantage of blood over marrow allografts. Blood 1995;85:1659-1665.
6. Lasky LC, Hurd DD, Smith JA, et al. Peripheral blood stem cell collection and use in Hodgkin's disease. Comparison with marrow in autologous transplantation. Transfusion 1989;29:323-327. (Pubitemid 19163921)
7. Ottinger HD, Beelen DW, Scheulen B, et al. Improved immune reconstitution after allotransplantation of peripheral blood stem cells instead of bone marrow. Blood 1996;88:2775-2779. (Pubitemid 26327533)
8. Henon PR, Liang H, Beck-Wirth G, et al. Comparison of hematopoietic and immune recovery after autologous bone marrow or blood stem cell transplants. Bone Marrow Transplant 1992;9:285-291.
9. Cashen AF, Lazarus HM, Devine SM. Mobilizing stem cells from normal donors: is it possible to improve upon G-CSF? Bone Marrow Transplant 2007;39:577-588. (Pubitemid 46729051)
10. Korbling M, Anderlini P. Peripheral blood stem cell versus bone marrow allotransplantation: does the source of hematopoietic stem cells matter? Blood 2001;98:2900-2908.
11. Bensinger WI, Martin PJ, Storer B, et al. Transplantation of bone marrow as compared with peripheral-blood cells from HLA-identical relatives in patients with hematologic cancers. N Engl J Med 2001;344:175-181. (Pubitemid 32064138)
12. Champlin RE, Schmitz N, Horowitz MM, et al. Blood stem cells compared with bone marrow as a source of hematopoietic cells for allogeneic transplantation. IBMTR Histocompatibility and Stem Cell Sources Working Committee and the European Group for Blood and Marrow Transplantation (EBMT). Blood 2000;95:3702-3709.
13. Berenson RJ, Bensinger WI, Hill RS, et al. Engraftment after infusion of CD34+ marrow cells in patients with breast cancer or neuroblastoma. Blood 1991;77:1717-1722.
14. Civin CI, Strauss LC, Brovall C, et al. Antigenic analysis of hematopoiesis. III. A hematopoietic progenitor cell surface antigen defined by a monoclonal antibody raised against KG-1a cells. J Immunol 1984;133:157-165. (Pubitemid 14076703)
15. Siena S, Bregni M, Brando B, et al. Flow cytometry for clinical estimation of circulating hematopoietic progenitors for autologous transplantation in cancer patients. Blood 1991;77:400-409.
16. Healy L, May G, Gale K, et al. The stem cell antigen CD34 functions as a regulator of hematopoietic cell adhesion. Proc Natl Acad Sci USA 1995;92:12240-12244.
17. Nervi B, Link DC, DiPersio JF. Cytokines and hematopoietic stem cell mobilization. J Cell Biochem 2006;99:690-705. (Pubitemid 44521989)
18. Peled A, Petit I, Kollet O, et al. Dependence of human stem cell engraftment and repopulation of NOD/SCID mice on CXCR4. Science 1999;283:845-848.
19. Levesque JP, Sims NA, Bendall LJ, et al. Endosteal niches and lymphopoiesis are inhibited during G-CSF induced hematopoietic stem cell mobilization. Blood 2008;112:320a.
20. Richman CM, Weiner RS, Yankee RA. Increase in circulating stem cells following chemotherapy in man. Blood 1976;47:1031-1039.
21. Olavarria E, Kanfer EJ. Selection and use of chemotherapy with hematopoietic growth factors for mobilization of peripheral blood progenitor cells. Curr Opin Hematol 2000;7:191-196. (Pubitemid 30213154)
22. Ballestrero A, Ferrando F, Garuti A, et al. Comparative effects of three cytokine regimens after high-dose cyclophosphamide: granulocyte colony-stimulating factor, granulocyte-macrophage colony-stimulating factor (GM-CSF), and sequential interleukin-3 and GM-CSF. J Clin Oncol 1999;17:1296.
23. Gojo I, Guo C, Sarkodee-Adoo C, et al. High-dose cyclophosphamide with or without etoposide for mobilization of peripheral blood progenitor cells in patients with multiple myeloma: efficacy and toxicity. Bone Marrow Transplant 2004;34:69-76. (Pubitemid 39022960)
24. To LB, Shepperd KM, Haylock DN, et al. Single high doses of cyclophosphamide enable the collection of high numbers of hemopoietic stem cells from the peripheral blood. Exp Hematol 1990;18:442-447. (Pubitemid 20250496)
25. Pusic I, Jiang SY, Landua S, et al. Impact of mobilization and remobilization strategies on achieving sufficient stem cell yields for autologous transplantation. Biol Blood Marrow Transplant 2008;14:1045-1056.
26. Gianni AM, Siena S, Bregni M, et al. Granulocytemacrophage colony-stimulating factor to harvest circulating haemopoietic stem cells for autotransplantation. Lancet 1989;2:580-585. (Pubitemid 19216206)
27. Socinski MA, Cannistra SA, Elias A, et al. Granulocytemacrophage colony stimulating factor expands the circulating haemopoietic progenitor cell compartment in man. Lancet 1988;1:1194-1198.
28. Lane TA, Law P, Maruyama M, et al. Harvesting and enrichment of hematopoietic progenitor cells mobilized into the peripheral blood of normal donors by granulocytemacrophage colony-stimulating factor (GM-CSF) or G-CSF: potential role in allogeneic marrow transplantation. Blood 1995;85:275-282.
29. Montgomery M, Cottler-Fox M. Mobilization and collection of autologous hematopoietic progenitor/stem cells. Clin Adv Hematol Oncol 2007;5:127-136. (Pubitemid 46455272)
30. Cashen AF, Nervi B, DiPersio J. AMD3100: CXCR4 antagonist and rapid stem cell-mobilizing agent. Future Oncol 2007;3:19-27.
31. Copelan EA. Hematopoietic stem-cell transplantation. N Engl J Med 2006;354:1813-1826.
32. Semerad CL, Christopher MJ, Liu F, et al. G-CSF potently inhibits osteoblast activity and CXCL12 mRNA expression in the bone marrow. Blood 2005;106:3020-3027. (Pubitemid 41565894)
33. Levesque JP, Liu F, Simmons PJ, et al. Characterization of hematopoietic progenitor mobilization in protease-deficient mice. Blood 2004;104:65-72. (Pubitemid 38879839)
34. Amgen. Neupogen full prescribing information. Available online at: http://www.amgen. com/pdfs/misc/neupogen-pi.pdf, accessed 25 June 2008.
35. Fischmeister G, Gadner H. Granulocyte colony-stimulating factor versus granulocyte-macrophage colony-stimulating factor for collection of peripheral blood progenitor cells from healthy donors. Curr Opin Hematol 2000;7:150-155. (Pubitemid 30213147)
36. Bensinger W, Appelbaum F, Rowley S, et al. Factors that influence collection and engraftment of autologous peripheral-blood stem cells. J Clin Oncol 1995;13:2547-2555.
37. Watts MJ, Addison I, Ings SJ, et al. Optimal timing for collection of PBPC after glycosylated G-CSF administration. Bone Marrow Transplant 1998;21:365-368. (Pubitemid 28080472)
38. Stroncek DF, Matthews CL, Follmann D, et al. Kinetics of G-CSF-induced granulocyte mobilization in healthy subjects: effects of route of administration and addition of dexamethasone. Transfusion 2002;42:597-602.
39. Koenigsmann M, Jentsch-Ullrich K, Mohren M, et al. The role of diagnosis in patients failing peripheral blood progenitor cell mobilization. Transfusion 2004;44:777-784. (Pubitemid 38608258)
40. Visani G, Lemoli RM, Tosi P, et al. Fludarabine-containing regimens severely impair peripheral blood stem cells mobilization and collection in acute myeloid leukaemia patients. Br J Haematol 1999;105:775-779. (Pubitemid 29277040)
41. Arbona C, Prosper F, Benet I, et al. Comparison between once a day vs. twice a day G-CSF for mobilization of peripheral blood progenitor cells (PBPC) in normal donors for allogeneic PBPC transplantation. Bone Marrow Transplant 1998;22:39-45. (Pubitemid 28330534)
42. Kroger N, Zeller W, Hassan HT, et al. Stem cell mobilization with G-CSF alone in breast cancer patients: higher progenitor cell yield by delivering divided doses (2 × 5 μg/kg) compared to a single dose (1 × 10 μg/kg). Bone Marrow Transplant 1999;23:125-129. (Pubitemid 29048212)
43. Kroger N, Renges H, Kruger W, et al. A randomized comparison of once versus twice daily recombinant human granulocyte colony-stimulating factor (filgrastim) for stem cell mobilization in healthy donors for allogeneic transplantation. Br J Haematol 2000;111:761-765. (Pubitemid 32098912)
44. Kroger N, Sonnenberg S, Cortes-Dericks L, et al. Kinetics of G-CSF and CD34+ cell mobilization after once or twice daily stimulation with rHu granulocyte-stimulating factor (lenograstim) in healthy volunteers: an intraindividual crossover study. Transfusion 2004;44:104-110. (Pubitemid 38177144)
45. Amgen. Neulasta full prescribing information. Available online at: http://www.amgen. com/pdfs/misc/neulasta-pi.pdf, accessed 25 June 2008.
46. Kroschinsky F, Holig K, Ehninger G. The role of pegfilgrastim in mobilization of hematopoietic stem cells. Transfus Apher Sci 2008;38:237-244.
47. Bruns I, Steidl U, Kronenwett R, et al. A single dose of 6 or 12 mg of pegfilgrastim for peripheral blood progenitor cell mobilization results in similar yields of CD34+ progenitors in patients with multiple myeloma. Transfusion 2006;46:180-185. (Pubitemid 43381751)
48. Steidl U, Fenk R, Bruns I, et al. Successful transplantation of peripheral blood stem cells mobilized by chemotherapy and a single dose of pegylated G-CSF in patients with multiple myeloma. Bone Marrow Transplant 2005;35:33-36. (Pubitemid 40090053)
49. Devine SM, Vij R, Rettig M, et al. Rapid mobilization of functional donor hematopoietic cells without G-CSF using AMD3100, an antagonist of the CXCR4/SDF-1 interaction. Blood 2008;112:990-998.
50. DiPersio J, Stadtmauer EA, Nademanee AP, et al. A phase III, multicenter, randomized, double-blind, placebo-controlled, comparative trial of AMD3100 (Plerixafor) +G-CSF vs. G-CSF+placebo for mobilization in multiple myeloma (MM) patients for autologous hematopoietic stem cell (aHSC) transplantation. Blood 2007;110(Suppl):445 (Abstract).
51. DiPersio JF, Micallef I, Stiff PJ, et al. A phase III, multicenter, randomized, double-blind, placebo controlled, comparative trial of AMD3100 (Plerixafor) +G-CSF vs. placebo+G-CSF in non-Hodgkin's lymphoma (NHL) patients for autologous hematopoietic stem cell (aHSC) transplantation. Blood 2007;110(Suppl):601 (Abstract).
52. Calandra G, McCarty J, McGuirk J, et al. AMD3100 plus G-CSF can successfully mobilize CD34+ cells from non-Hodgkin's lymphoma, Hodgkin's disease and multiple myeloma patients previously failing mobilization with chemotherapy and/or cytokine treatment: compassionate use data. Bone Marrow Transplant 2008;41:331-338. (Pubitemid 351330727)
53. Micallef I, Stiff PJ, DiPersio JF, et al. Successful stem cell mobilization rescue by AMD3100 (Plerixafor) +G-CSF for patients who failed primary mobilization: results from the phase III (3101-NHL) study. Blood 2007;110(Suppl):602 (Abstract).
54. Anderlini P, Przepiorka D, Seong D, et al. Clinical toxicity and laboratory effects of granulocyte-colony-stimulating factor (filgrastim) mobilization and blood stem cell apheresis from normal donors, and analysis of charges for the procedures. Transfusion 1996;36:590-595. (Pubitemid 26256425)
55. Devine SM, Andritsos L, Todt L, et al. A pilot study evaluating the safety and efficacy of AMD3100 for the mobilization and transplantation of HLA-matched sibling donor hematopoietic stem cells in patients with advanced hematological malignancies. Blood 2005;106(Suppl):299 (Abstract).
56. Bayer Health Care. Leukine prescribing information. Available online at: http://www.leukine.com/hcp/index.jsp, accessed 9 March 2009.
57. Devine SM, Brown RA, Mathews V, et al. Reduced risk of acute GVHD following mobilization of HLA-identical sibling donors with GM-CSF alone. Bone Marrow Transplant 2005;36:531-538. (Pubitemid 43118148)
58. Hendrix CW, Collier AC, Lederman MM, et al. Safety, pharmacokinetics, and antiviral activity of AMD3100, a selective CXCR4 receptor inhibitor, in HIV-1 infection. J Acquir Immune Defic Syndr 2004;37:1253-1262. (Pubitemid 39281506)
59. Flomenberg N, Devine SM, Dipersio JF, et al. The use of AMD3100 plus G-CSF for autologous hematopoietic progenitor cell mobilization is superior to G-CSF alone. Blood 2005;106:1867-1874. (Pubitemid 41208607)
60. Platzbecker U, Prange-Krex G, Bornhauser M, et al. Spleen enlargement in healthy donors during G-CSF mobilization of PBPCs. Transfusion 2001;41:184-189. (Pubitemid 32220507)
61. Stroncek D, Shawker T, Follmann D, et al. G-CSF-induced spleen size changes in peripheral blood progenitor cell donors. Transfusion 2003;43:609-613. (Pubitemid 36506357)
62. Stroncek DF, Dittmar K, Shawker T, et al. Transient spleen enlargement in peripheral blood progenitor cell donors given G-CSF. J Transl Med 2004;2:25.
63. Falzetti F, Aversa F, Minelli O, et al. Spontaneous rupture of spleen during peripheral blood stem-cell mobilisation in a healthy donor. Lancet 1999;353:555. (Pubitemid 29078428)
64. Balaguer H, Galmes A, Ventayol G, et al. Splenic rupture after granulocyte-colony-stimulating factor mobilization in a peripheral blood progenitor cell donor. Transfusion 2004;44:1260-1261. (Pubitemid 38989764)
65. Lindemann A, Rumberger B. Vascular complications in patients treated with granulocyte colony-stimulating factor (G-CSF). Eur J Cancer A 1993;29:2338-2339. (Pubitemid 24053021)
66. Hsia CC, Linenberger M, Mangel J, et al. Acute myeloid leukemia in a healthy hematopoietic stem cell donor following past exposure to a short course of G-CSF. Bone Marrow Transpl 2008;42:431-432.
67. Peters WP, Rosner G, Ross M, et al. Comparative effects of granulocyte-macrophage colony-stimulating factor (GM-CSF) and granulocyte colony-stimulating factor (G-CSF) on priming peripheral blood progenitor cells for use with autologous bone marrow after high-dose chemotherapy. Blood 1993;81:1709-1719. (Pubitemid 23101582)
68. Weaver CH, Schulman KA, Wilson-Relyea B, et al. Randomized trial of filgrastim, sargramostim, or sequential sargramostim and filgrastim after myelosuppressive chemotherapy for the harvesting of peripheral-blood stem cells. J Clin Oncol 2000;18:43-53. (Pubitemid 30036335)
69. Gazitt Y. Comparison between granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor in the mobilization of peripheral blood stem cells. Curr Opin Hematol 2002;9:190-198. (Pubitemid 34275964)
70. Spitzer G, Adkins D, Mathews M, et al. Randomized comparison of G-CSF + GM-CSF vs G-CSF alone for mobilization of peripheral blood stem cells: effects on hematopoietic recovery after high-dose chemotherapy. Bone Marrow Transplant 1997;20:921-930. (Pubitemid 27510954)
71. Ravagnani F, Siena S, Bregni M, et al. Large-scale collection of circulating haematopoietic progenitors in cancer patients treated with high-dose cyclophosphamide and recombinant human GM-CSF. Eur J Cancer 1990;26:562-564. (Pubitemid 20259328)
72. Narayanasami U, Kanteti R, Morelli J, et al. Randomized trial of filgrastim versus chemotherapy and filgrastim mobilization of hematopoietic progenitor cells for rescue in autologous transplantation. Blood 2001;98:2059-2064.
73. Bourhis JH, Bouko Y, Koscielny S, et al. Relapse risk after autologous transplantation in pateints with newly diagnosed myeloma is not related with infused tumor cell load and the outcome is not improved by CD34+ cell selection: long term follow-up of an EBMT phase III randomized trial. Haematologica 2007;92:1083-1090. (Pubitemid 350144215)
74. Lapidot T, Petit I. Current understanding of stem cell mobilization: the roles of chemokines, proteolytic enzymes, adhesion molecules, cytokines, and stromal cells. Exp Hematol 2002;30:973-981. (Pubitemid 35286613)
75. Petit I, Szyper-Kravitz M, Nagler A, et al. G-CSF induces stem cell mobilization by decreasing bone marrow SDF-1 and up-regulating CXCR4. Nat Immunol 2002;3:687-694. (Pubitemid 34752479)
76. Plerixafor: AMD 3100, AMD3100, JM 3100, SDZ SID 791. Drugs R D 2007;8:113-119.
77. De Clercq E. The bicyclam AMD3100 story. Nat Rev Drug Discov 2003;2:581-587. (Pubitemid 37361749)
78. Shepherd RM, Capoccia BJ, Devine SM, et al. Angiogenic cells can be rapidly mobilized and efficiently harvested from the blood following treatment with AMD3100. Blood 2006;108:3662-3667. (Pubitemid 44864542)
79. Larochelle A, Krouse A, Metzger M, et al. AMD3100 mobilizes hematopoietic stem cells with long-term repopulating capacity in nonhuman primates. Blood 2006;107:3772-3778.
80. Hess DA, Bonde J, Craft TP, et al. Human progenitor cells rapidly mobilized by AMD3100 repopulate NOD/SCID mice with increased frequency in comparison to cells from the same donor mobilized by granulocyte colony stimulating factor. Biol Blood Marrow Transplant 2007;13:398-411. (Pubitemid 46421895)
81. Devine SM, Flomenberg N, Vesole DH, et al. Rapid mobilization of CD34+ cells following administration of the CXCR4 antagonist AMD3100 to patients with multiple myeloma and non-Hodgkin's lymphoma. J Clin Oncol 2004;22:1095-1102. (Pubitemid 41095043)
82. Drug.com Web site. Mozobil: Genzyme files applications for approval of mozobil in the United States and Europe. Available online at: http://www.drugs.com/nda/mozobil-080 617.html, accessed 25 June 2008.
83. Uy GL, Rettig MP, Ramirez P, et al. Kinetics of human and murine mobilization of acute myeloid leukemia in response to AMD 3100. Blood 2001;110:867a.
84. Runnels JM, Azab A, Pitsillides C, et al. In vivo mobilization of multiple myeloma cells out of the bone marrow using the CXCR4 inhibitor AMD 3100 and Bortezomib: implications for sensitivity of myeloma cells to apoptosis. Blood 2007;110(Suppl):2501a (Abstract).
85. Azab AK, Runnels JM, Pitsillides C, et al. The CXCR4 Inhibitor AMD 3100 disrupts the interaction of multiple myeloma cells and the bone marrow microenvironment and enhances their sensitivity to therapy. Blood 2009;113:4241-4257.
86. Burger JA, Peled A. CXCR4 antagonists: targeting the microenvironment in leukemia and other cancers. Leukemia 2009;23:43-52.
87. Desikan KR, Tricot G, Munshi NC, et al. Preceding chemotherapy, tumour load and age influence engraftment in multiple myeloma patients mobilized with granulocyte colony-stimulating factor alone. Br J Haematol 2001;112:242-247. (Pubitemid 32151178)
88. Tricot G, Jagannath S, Vesole D, et al. Peripheral blood stem cell transplants for multiple myeloma: identification of favorable variables for rapid engraftment in 225 patients. Blood 1995;85:588-596.
89. Bensinger WI, Longin K, Appelbaum F, et al. Peripheral blood stem cells (PBSCs) collected after recombinant granulocyte colony stimulating factor (rhG-CSF): an analysis of factors correlating with the tempo of engraftment after transplantation. Br J Haematol 1994;87:825-831. (Pubitemid 24264657)
90. Negrin RS, Kusnierz-Glaz CR, Still BJ, et al. Transplantation of enriched and purged peripheral blood progenitor cells from a single apheresis product in patients with non-Hodgkin's lymphoma. Blood 1995;85:3334-3341.
91. Jillella AP, Ustun C. What is the optimum number of CD34+ peripheral blood stem cells for an autologous transplant? Stem Cells Dev 2004;13:598-606. (Pubitemid 40052636)
92. Gandhi MK, Jestice K, Scott MA, et al. The minimum CD34 threshold depends on prior chemotherapy in autologous peripheral blood stem cell recipients. Bone Marrow Transplant 1999;23:9-13. (Pubitemid 29050172)
93. Glaspy JA, Shpall EJ, LeMaistre CF, et al. Peripheral blood progenitor cell mobilization using stem cell factor in combination with filgrastim in breast cancer patients. Blood 1997;90:2939-2951. (Pubitemid 27444188)
94. Ketterer N, Salles G, Raba M, et al. High CD34 (+) cell counts decrease hematologic toxicity of autologous peripheral blood progenitor cell transplantation. Blood 1998;91:3148-3155. (Pubitemid 28193863)
95. Weaver CH, Hazelton B, Birch R, et al. An analysis of engraftment kinetics as a function of the CD34 content of peripheral blood progenitor cell collections in 692 patients after the administration of myeloablative chemotherapy. Blood 1995;86:3961-3969.
96. Siena S, Schiavo R, Pedrazzoli P, Carlo-Stella C. Therapeutic relevance of CD34 cell dose in blood cell transplantation for cancer therapy. J Clin Oncol 2000;18:1360-1377. (Pubitemid 30159857)
97. Zaucha JM, Gooley T, Bensinger WI, et al. CD34 cell dose in granulocyte colony-stimulating factor-mobilized peripheral blood mononuclear cell grafts affects engraftment kinetics and development of extensive chronic graft-versus-host disease after human leukocyte antigenidentical sibling transplantation. Blood 2001;98:3221-3227.
98. Ninan MJ, Flowers CR, Roback JD, et al. Posttransplant thrombopoiesis predicts survival in patients undergoing autologous hematopoietic progenitor cell transplantation. Biol Blood Marrow Transplant 2007;13:895-904. (Pubitemid 47055383)
99. Sola C, Maroto P, Salazar R, et al. Bone marrow transplantation: prognostic factors of peripheral blood stem cell mobilization with cyclophosphamide and filgrastim (r-metHuG-CSF): the CD34+ cell dose positively affects the time to hematopoietic recovery and supportive requirements after high-dose chemotherapy. Hematology 1999;4:195-209. (Pubitemid 30011407)
100. Dreger P, Kloss M, Petersen B, et al. Autologous progenitor cell transplantation: prior exposure to stem cell-toxic drugs determines yield and engraftment of peripheral blood progenitor cell but not of bone marrow grafts. Blood 1995;86:3970-3978.
101. Weaver CH, Schwartzberg LS, Birch R, et al. Collection of peripheral blood progenitor cells after the administration of cyclophosphamide, etoposide, and granulocyte-colonystimulating factor: an analysis of 497 patients. Transfusion 1997;37:896-903.
102. Haas R, Mohle R, Fruhauf S, et al. Patient characteristics associated with successful mobilizing and autografting of peripheral blood progenitor cells in malignant lymphoma. Blood 1994;83:3787-3794. (Pubitemid 24175570)
103. Kasparu H, Krieger O, Girschikofsky M, et al. Factors influencing the timing of peripheral blood stem cell collection (PBSC). Transfus Sci 1996;17:595-600.
104. Anderlini P, Przepiorka D, Seong C, et al. Factors affecting mobilization of CD34+ cells in normal donors treated with filgrastim. Transfusion 1997;37:507-512. (Pubitemid 27203941)
105. De La Rubia J, Arbona C, de Arriba F, et al. Analysis of factors associated with low peripheral blood progenitor cell collection in normal donors. Transfusion 2002;42:4-9.
106. Neben S, Hellman S, Montgomery M, et al. Hematopoietic stem cell deficit of transplanted bone marrow previously exposed to cytotoxic agents. Exp Hematol 1993;21:156-162. (Pubitemid 24216749)
107. Schmidt-Hieber M, Busse A, Reufi B, et al. Bendamustine, but not fludarabine, exhibits a low stem cell toxicity in vitro. J Cancer Res Clin Oncol 2009;135:227-234.
108. Kumar S, Dispenzieri A, Lacy MQ, et al. Impact of lenalidomide therapy on stem cell mobilization and engraftment post-peripheral blood stem cell transplantation in patients with newly diagnosed myeloma. Leukemia 2007;21:2035-2042. (Pubitemid 47299979)
109. Mazumder A, Kaufman J, Niesvizky R, et al. Effect of lenalidomide therapy on mobilization of peripheral blood stem cells in previously untreated multiple myeloma patients. Leukemia 2008;22:1280-1281; author reply 1281-1282. (Pubitemid 351833803)
110. Paripati H, Stewart AK, Cabou S, et al. Compromised stem cell mobilization following induction therapy with lenalidomide in myeloma. Leukemia 2008;22:1282-1284. (Pubitemid 351833805)
111. GlaxoSmithKline. Bexxar complete prescribing information. Available online at: http://us.gsk.com/products/assets/us-bexxar.pdf, accessed 17 April 2008.
112. Cell Therapeutics Inc. Available online at: http://www.zeva lin. com/pdf/Zevalin-PI-website.pdf, accessed 17 April 2008.
113. Zhang MM, Gopal AK. Radioimmunotherapy-based conditioning regimens for stem cell transplantation. Semin Hematol 2008;45:118-125. (Pubitemid 351444840)
114. Vose JM, Sharp G, Chan WC, et al. Autologous transplantation for aggressive non-Hodgkin's lymphoma: results of a randomized trial evaluating graft source and minimal residual disease. J Clin Oncol 2002;20:2344-2352. (Pubitemid 34441662)
115. Kessinger A, Armitage JO, Smith DM, et al. High-dose therapy and autologous peripheral blood stem cell transplantation for patients with lymphoma. Blood 1989;74:1260-1265. (Pubitemid 19227433)
116. Chao NJ, Schriber JR, Grimes K, et al. Granulocyte colony-stimulating factor "mobilized" peripheral blood progenitor cells accelerate granulocyte and platelet recovery after high-dose chemotherapy. Blood 1993;81:2031-2035. (Pubitemid 23106716)
117. To LB, Roberts MM, Haylock DN, et al. Comparison of haematological recovery times and supportive care requirements of autologous recovery phase peripheral blood stem cell transplants, autologous bone marrow transplants and allogeneic bone marrow transplants. Bone Marrow Transplant 1992;9:277-284.
118. Bensinger W, Singer J, Appelbaum F, et al. Autologous transplantation with peripheral blood mononuclear cells collected after administration of recombinant granulocyte stimulating factor. Blood 1993;81:3158-3163. (Pubitemid 23162138)
119. Gazitt Y, Freytes CO, Akay C, et al. Improved mobilization of peripheral blood CD34+ cells and dendritic cells by AMD3100 plus granulocyte-colony- stimulating factor in non-Hodgkin's lymphoma patients. Stem Cells Dev 2007;16:657-666. (Pubitemid 47378738)
120. Gazitt Y, Akay C, Thomas C III. No polarization of type 1 or type 2 precursor dendritic cells in peripheral blood stem cell collections of non-Hodgkin's lymphoma patients mobilized with cyclophosphamide plus G-CSF, GM-CSF, or GM-CSF followed by G-CSF. Stem Cells Dev 2006;15:269-277. (Pubitemid 43726505)